---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126382"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:50:36.601094+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Sutro Biopharma Q3 2024: revenue $8.5M, cash $388.3M, luvelta registrational trial underway

## Summary
- Cash, equivalents, and marketable securities $388.3M as of September 30, 2024.
- Revenue $8.5M for Q3 2024, down from $16.9M in Q3 2023 (49.7% decrease).
- Total operating expenses $76.4M, up from $60.9M in Q3 2023; R&D $62.1M, G&A $14.3M.
- Realized gain of $32.1M from sale of Vaxcyte shares; no remaining Vaxcyte holdings.
- Initiated registrational trial for luvelta in pediatric leukemia; IND for STRO-004 expected H2 2025.

## SEC filing metadata
- accession: 0000950170-24-126382
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/0000950170-24-126382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/stro-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126382
- JSON: https://secwatch.observer/filing/0000950170-24-126382.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.